CompletedPhase 1NCT05870839

Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vaccine Company, Inc.
Principal Investigator
Justin Ortiz, MD, MS
University of Maryland
Intervention
VXCO-100(biological)
Enrollment
121 target
Eligibility
18 years · All sexes
Timeline
20232024

Study locations (3)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05870839 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials